These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21505102)

  • 1. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.
    Kvinlaug BT; Chan WI; Bullinger L; Ramaswami M; Sears C; Foster D; Lazic SE; Okabe R; Benner A; Lee BH; De Silva I; Valk PJ; Delwel R; Armstrong SA; Döhner H; Gilliland DG; Huntly BJ
    Cancer Res; 2011 Jun; 71(12):4117-29. PubMed ID: 21505102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.
    Tijchon E; Yi G; Mandoli A; Smits JGA; Ferrari F; Heuts BMH; Wijnen F; Kim B; Janssen-Megens EM; Schuringa JJ; Martens JHA
    PLoS One; 2019; 14(12):e0226435. PubMed ID: 31869378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.
    Fortier JM; Payton JE; Cahan P; Ley TJ; Walter MJ; Graubert TA
    Leukemia; 2010 May; 24(5):950-7. PubMed ID: 20376082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
    Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
    Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
    Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.
    Link KA; Lin S; Shrestha M; Bowman M; Wunderlich M; Bloomfield CD; Huang G; Mulloy JC
    Proc Natl Acad Sci U S A; 2016 Aug; 113(32):9075-80. PubMed ID: 27457952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
    Rulina AV; Spirin PV; Prassolov VS
    Biochemistry (Mosc); 2010 Dec; 75(13):1650-66. PubMed ID: 21417999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
    Engel ME; Hiebert SW
    Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.
    Abdul-Nabi AM; Yassin ER; Varghese N; Deshmukh H; Yaseen NR
    PLoS One; 2010 Aug; 5(8):e12464. PubMed ID: 20805992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
    Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
    Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
    Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
    Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
    Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
    Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
    Jankovic D; Gorello P; Liu T; Ehret S; La Starza R; Desjobert C; Baty F; Brutsche M; Jayaraman PS; Santoro A; Mecucci C; Schwaller J
    Blood; 2008 Jun; 111(12):5672-82. PubMed ID: 18388181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with
    Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1.
    Pineault N; Buske C; Feuring-Buske M; Abramovich C; Rosten P; Hogge DE; Aplan PD; Humphries RK
    Blood; 2003 Jun; 101(11):4529-38. PubMed ID: 12543865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
    Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.